Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Synopsis of current research projects
                          • Synopsis of completed research projects
                            • Decision Support Documents for the Austrian Appraisal Board
                              • HTA-Information Service Rapid Reviews
                                • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                  • Horizon Scanning of Medicines - Reports and Fact Sheets
                                    • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                      • Evaluation of individual medical procedures - Reports
                                        • All projects in an overview
                                          • Supervised Master's Theses
                                            Video
                                            Video: What is HTA?    
                                            • Home
                                            • Research Projects
                                            • Synopsis of completed research projects
                                            • Health Services Research (HSR) in oncology: Analysis of Austrian data

                                            Health Services Research (HSR) in oncology: Analysis of Austrian data

                                            Fotolia-45417819-xs3
                                            Research area: Oncology

                                            Project leaders: Nicole Grössmann-Waniek

                                            Project team: Nicole Grössmann-Waniek

                                            Supported by DexHelpp (data-requirements and -acquisition), Martin Robausch
                                            Duration: January 2018 – December 2019

                                            Publication:

                                            Grössmann N, Robausch M, Willenbacher W, Wolf S, Simon J, Wild C. “Magnitude of clinical benefit” of solid tumour drugs and their real-world application in the Austrian health care setting. Journal of Cancer Policy. 2020;25:100235.

                                            Background:
                                            Austria is among the leading countries with regard to the early adoption and availability of new cancer drugs [1, 2]. Therefore, an early awareness system called ‘Horizon Scanning in Oncology’ (HSO) was developed and implemented by the Austrian Ludwig Boltzmann Institute for Health Technology Assessment (LBI–HTA) in 2009. The HSO system shall provide information to decision makers (hospital administrators, drug commissions, social insurance organisations) to contribute to rational decision making and facilitate estimations on budget implications (https://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie-berichte/en). Due to the increasing uncertainty of the benefit-risk profiles of some oncological therapies there is a need of more stringent benefit assessments [3, 4, 5]. In Austria some (but not all, n = 33 in 2017) cancer therapies are included in the national hospital benefit catalogue. Decisions on specific oncological treatment schemes are exclusively taken within the regional public hospital cooperation´s. Some of the oncology drugs listed in the Austrian hospital benefit catalogue were uniformly assessed negatively regarding their efficacy as well as their cost-effectiveness [2].

                                            Project aim and research question:
                                            The project aims to provide an overview on both the frequency of reimbursement of those oncological therapies included in the national hospital benefit catalogue for different tumour patients (diagnosis and indications) as well as the respective patient characteristics (age, socio-economic status) and also therapy-related information (follow-up therapies, treatment of side effects, survival etc.). The overview will provide a general picture for all reimbursed oncological therapies in Austria.

                                            Potential questions to be answered:

                                            • Regional variances in the use of oncological therapies included in the national hospital benefit catalogue (in different tumour indications)
                                            • Regional variances with regards to age, gender and socio-economic status
                                            • Frequency and duration of hospitalisations
                                            •  Quantity and quality of different physician contacts
                                            •  Quantity and quality of additional extramural care, incl. mental health, pain etc. interventions
                                            • Sick leaves

                                            Methods:

                                            (1)  Analysis of routine data

                                            (2)  Aggregated presentation of results at the level of the nine federal states

                                            (3)  Investigation and analysis of pre-marketing and post-marketing clinical studies of oncological therapies in Austria

                                            Time management:

                                            • Jan–March 2018: Definition data-requirements, -acquisition
                                            • April–Dec 2018: Data-analysis
                                            •  Jan–December 2019: Reporting, Peer-Review

                                            Literature:

                                            [1]    Bengt Jönsson et al., (2016) Comparator Report on Patient Access to Cancer Medicines in Europe Revisited, http://ihe.se/wp-content/uploads/2016/08/IHE-Report_2016_4.pdf

                                            [2]    Grössmann, N., Wild, C., Mayer, J. (2016) Onkologika: Übersicht zu Nutzenbewertungen und Refundierungspolitiken in Europa. Rapid Assessment LBI-HTA Nr. 08. 2016. Wien: Ludwig Boltzmann Institut für Health Technology Assessment.

                                            [3]    Deutsches Ärzteblatt (2017): Ruf nach schärferer Nutzenbewertung von Krebsmedikamenten. 18. Dez. https://www.aerzteblatt.de/nachrichten/87079/Ruf-nach-schaerferer-Nutzenbewertung-von-Krebsmedikamenten

                                            [4]    Light DW, Lexchin J. Why do cancer drugs get such an easy ride? BMJ 2015; 350:h2068.

                                            [5]          Apolone G, Tafuri G, Trotta F, et al. A new anti-cancer drug in the market: good news for investors or for patients? Eur J Cancer 2008; 44:1786–8.

                                            • News
                                              • Job advertisement: Assistant Finance Department/HR/ Science
                                                • Job advertisement in AIHTA - Job advertisement: Senior researcher
                                                  • Announcements
                                                    • Events
                                                      • Newsletter
                                                        • Press release on our reports
                                                          • Press photos
                                                          • About us
                                                            • Evaluation
                                                              • History
                                                                • Methods
                                                                  • Team
                                                                    • Shareholder & organization chart
                                                                      • Stakeholder involvement
                                                                        • Press clippings
                                                                        • Research areas
                                                                          • Oncology
                                                                            • High tech medicine
                                                                              • Rehabilitation and occupational therapy
                                                                                • Prevention and screening
                                                                                  • Psychological & psychiatric interventions
                                                                                    • Health economics
                                                                                      • European collaboration
                                                                                        • HTA-methods & steering instruments
                                                                                          • Complementary medicine
                                                                                          • Research Projects
                                                                                            • Synopsis of current research projects
                                                                                              • Synopsis of completed research projects
                                                                                                • Decision Support Documents for the Austrian Appraisal Board
                                                                                                  • HTA-Information Service Rapid Reviews
                                                                                                    • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                                      • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                                        • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                                          • Evaluation of individual medical procedures - Reports
                                                                                                            • All projects in an overview
                                                                                                              • Supervised Master's Theses
                                                                                                              • Publications
                                                                                                                • Repository
                                                                                                                  • HTA-Newsletter
                                                                                                                    • Annual Reports
                                                                                                                    • Search
                                                                                                                      Netzwerk
                                                                                                                      • Eunethta
                                                                                                                      • Ebm
                                                                                                                      • Inahta
                                                                                                                      • Dexhelpp
                                                                                                                      Shareholder
                                                                                                                      • Bmfg
                                                                                                                      • Sv
                                                                                                                      • Wgfond
                                                                                                                      • Noe
                                                                                                                      • Ooghfond
                                                                                                                      • Ghls
                                                                                                                      • Tirol
                                                                                                                      • Vorarlberg
                                                                                                                      • Kghfond
                                                                                                                      • Ghpf
                                                                                                                      • Burgef
                                                                                                                      • Contact
                                                                                                                        • Imprint
                                                                                                                          • Privacy Notice
                                                                                                                            • Newsletter
                                                                                                                              • Sitemap
                                                                                                                                © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                                • Log in